Abstract
Previous research has suggested that thyroid hormone receptor alpha 1 (THRα1), a hormone responsive splice variant, may play a role in breast cancer progression. Whether THRα1 can be exploited for anti-cancer therapy is unknown. The antiproliferative and antitumor effects of dronedarone, an FDA-approved anti-arrhythmic drug which has been shown to antagonize THRα1, was evaluated in breast cancer cell lines in vitro and in vivo. The THRα1 splice variant and the entire receptor, THRα, were also independently targeted using siRNA to determine the effect of target knockdown in vitro. In our study, dronedarone demonstrates cytotoxic effects in vitro and in vivo in breast cancer cell lines at doses and concentrations that may be clinically relevant. However, knockdown of either THRα1 or THRα did not cause substantial anti-proliferative or cytotoxic effects in vitro, nor did it alter the sensitivity to dronedarone. Thus, we conclude that dronedarone's cytotoxic effect in breast cancer cell lines are independent of THRα or THRα1 antagonism. Further, the depletion of THRα or THRα1 does not affect cell viability or proliferation. Characterizing the mechanism of dronedarone's anti-tumor action may facilitate drug repurposing or the development of new anti-cancer agents.
Introduction
Breast cancer remains a leading cause of cancer-related mortality, driving the search for novel therapeutic interventions. Drug repurposing—the identification of new clinical applications for existing, approved medications—represents a strategic approach to accelerate treatment development. Recent interest has focused on thyroid hormone receptors (THRs), specifically the THRα1 splice variant, which is linked to increased cellular proliferation and poor clinical outcomes. Dronedarone, an FDA-approved anti-arrhythmic agent, is a known antagonist of THRα1. This study evaluates the potential of repurposing Dronedarone for breast cancer treatment and investigates whether its efficacy is mediated through THRα1 inhibition.
Methods
This investigation employed a multi-disciplinary methodology:
- Bioinformatics: RNA-seq data from 1,099 samples (1,092 primary and 7 metastatic) in The Cancer Genome Atlas (TCGA) were analyzed to correlate THRα and THRα1 expression with patient survival across various subtypes.
- In Vitro Assays: Dronedarone was screened against 18 breast cancer cell lines representing Luminal A/B, HER2+, and Triple Negative subtypes. Growth inhibition was measured via SRB assays to determine $IC_{50}$ values, and apoptosis was quantified using Annexin-V/PI flow cytometry.
- In Vivo Xenografts: Human HCC1954 breast cancer cells were implanted into mice. Subjects received Dronedarone (20 mg/kg) to evaluate tumor growth inhibition.
- Genetic Validation: siRNA was used to silence THRα and THRα1 genes to determine if receptor depletion mimics the drug's effects or alters cellular sensitivity to Dronedarone.
Results
Prognostic Significance of THRα1
Analysis of the TCGA dataset confirmed that high THRα1 expression is a significant negative prognostic factor. This association was particularly evident in Luminal A ($p=0.04$) and Triple Negative (basal-like) subtypes.
Cytotoxic Efficacy of Dronedarone
Dronedarone demonstrated potent, dose-dependent cytotoxicity across the cell line panel, with $IC_{50}$ values between $2–4 \mu M$. These concentrations are potentially achievable in clinical settings. Flow cytometry confirmed the induction of both early and late apoptosis in all tested lines. In vivo, a well-tolerated dose of 20 mg/kg resulted in a 57.7% inhibition of tumor growth ($p=0.01$).
Independence from THRα1 Antagonism
Contrary to the initial hypothesis, genetic silencing of THRα or THRα1 did not significantly impact cell viability or proliferation. Furthermore, the knockdown of these receptors did not alter the sensitivity of the cells to Dronedarone. These findings indicate that while Dronedarone is a THRα1 antagonist, its anti-tumor activity is driven by an independent, off-target mechanism.
Discussion
Dronedarone effectively inhibits breast cancer growth both in vitro and in vivo at clinically relevant concentrations. However, the study definitively shows that this effect is independent of THRα or THRα1 antagonism. The actual molecular target remains to be identified, with potential candidates including ion channel inhibition or the downregulation of Topoisomerase IIα.
While the drug showed significant efficacy in mouse models, the therapeutic window was narrow, as higher doses (35–45 mg/kg) proved toxic. Future research should focus on identifying the specific off-target mechanism to enable the development of more potent and selective derivatives. Such efforts could lead to a new class of anti-cancer agents derived from the Dronedarone scaffold.
Summary updated